Changkyu Oh, Dr. rer. nat.
President / CEO
"We would like to contribute to the health and well-being of the humankind by innovating biotechnologies and creating new bioproducts."
After obtaining a PhD in Molecular Genetics in Germany, I have gained a wide array of experience in bio R&Ds and business projects since 2000 as a director at Macrogen and GCPharma and a CEO at ToolGen and ForHuman Tech. Humab is my second startup; it focuses on the development and commercialization of a transgenic antibody platform (SynTheseTM), which possesses the biggest market potential as the most advanced technology in the field of genome engineering rapidly growing powered by the newly developed CRISPR technology.